Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 10552
Species: Mus musculus
RGD Object: Gene
Symbol: Esr2
Name: estrogen receptor 2 (beta)
Acc ID: CHEBI:31638
Term: fulvestrant
Definition: A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.
Chemical ID: MESH:C070081
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
QualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
affects bindingEXP 6480464CTDfulvestrant binds to ESR2 protein

PMID:19913605
decreases expressionEXP 6480464CTDfulvestrant results in decreased expression of ESR2 mRNA alternative form

PMID:28356238
multiple interactionsEXP 6480464CTDEstradiol inhibits the reaction [Fulvestrant results in decreased expression of ESR2 mRNA alternative form], Fulvestrant inhibits the reaction [[[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with bisphenol A] results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [dioscin results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]], Fulvestrant inhibits the reaction [Estrogens results in increased activity of ESR2 protein polymorphism], Fulvestrant inhibits the reaction [sodium arsenite results in increased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [sodium arsenite results in increased expression of ESR2 protein]

PMID:17974624, PMID:24742230, PMID:26944108, PMID:28013213, PMID:28356238, PMID:30684567
affects bindingISORGD:25826480464CTDfulvestrant binds to ESR2 protein

PMID:19913605
affects bindingISORGD:692136480464CTDfulvestrant binds to ESR2 protein

PMID:17203231, PMID:19913605
affects expressionISORGD:692136480464CTDfulvestrant affects the expression of ESR2 protein

PMID:19270784
decreases expressionISORGD:692136480464CTDfulvestrant results in decreased expression of ESR2 protein

PMID:15950373, PMID:16202921, PMID:26988655
increases expressionISORGD:692136480464CTDfulvestrant results in increased expression of ESR2 protein

PMID:28882636
increases response to substanceISORGD:692136480464CTDESR2 protein results in increased susceptibility to fulvestrant

PMID:17638070
multiple interactionsISORGD:25826480464CTDfulvestrant binds to and results in decreased activity of ESR2 protein, fulvestrant inhibits the reaction [16 alpha-iodoestradiol binds to ESR2 protein], fulvestrant inhibits the reaction [[Ethinyl Estradiol co-treated with Triclosan] results in decreased expression of ESR2 mRNA], fulvestrant inhibits the reaction [naringin results in increased expression of ESR2 mRNA]

PMID:19570671, PMID:23261820, PMID:23596885, PMID:24782323, PMID:9048584
multiple interactionsISORGD:692136480464CTD6-OH-BDE-47 promotes the reaction [Fulvestrant results in decreased expression of ESR2 protein], Fulvestrant binds to and results in decreased activity of ESR2 protein, Fulvestrant inhibits the reaction [2, 2', 4, 4'-tetrabromodiphenyl ether results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [3, 3', 4, 5'-tetrahydroxystilbene results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [[Estradiol co-treated with ESR2 protein] results in increased expression of NOS3 mRNA], Fulvestrant inhibits the reaction [Androstane-3, 17-diol analog binds to and results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Androstane-3, 17-diol binds to and results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]], Fulvestrant inhibits the reaction [bisphenol A results in increased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Cadmium Chloride results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [Diarylheptanoids results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [diarylpropionitrile results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Dihydrotestosterone results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Dihydrotestosterone results in increased localization of ESR2 protein], Fulvestrant inhibits the reaction [Estradiol results in decreased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Estradiol results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Estradiol results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [Estradiol results in increased localization of ESR2 protein], Fulvestrant inhibits the reaction [Genistein results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]], Fulvestrant inhibits the reaction [Plant Preparations results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Resveratrol results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [rhapontigenin analog results in increased activity of ESR2 protein], Fulvestrant promotes the reaction [5-OH-BDE-47 results in decreased expression of ESR2 protein], Fulvestrant promotes the reaction [6-OH-BDE-47 affects the expression of ESR2 protein], Fulvestrant promotes the reaction [ESR1 protein binds to ESR2 protein]

PMID:14742696, PMID:15103026, PMID:15130599, PMID:15171712, PMID:15537743, PMID:17003281, PMID:17692514, PMID:17935960, PMID:18973785, PMID:19654927, PMID:20061804, PMID:24685904, PMID:25752796, PMID:26867312, PMID:26988655, PMID:28571686, PMID:28882636, PMID:29383186, PMID:29421333, PMID:30682495
Go Back to source page   Continue to Ontology report

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.